HTG Molecular Diagnostics (NASDAQ:HTGM) has been assigned a $8.00 price target by research analysts at HC Wainwright in a research note issued on Thursday. The brokerage currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s price target points to a potential upside of 141.69% from the company’s current price.
Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald initiated coverage on HTG Molecular Diagnostics in a research note on Thursday, September 20th. They issued a “buy” rating and a $7.00 target price on the stock. Zacks Investment Research upgraded HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Tuesday, August 14th. ValuEngine upgraded HTG Molecular Diagnostics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 8th. Finally, Craig Hallum initiated coverage on HTG Molecular Diagnostics in a research note on Monday, November 12th. They issued a “buy” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $6.80.
HTGM stock opened at $3.31 on Thursday. The company has a current ratio of 7.13, a quick ratio of 6.93 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $95.75 million, a price-to-earnings ratio of -1.85 and a beta of 2.00. HTG Molecular Diagnostics has a 1 year low of $1.71 and a 1 year high of $5.83.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Thursday, November 8th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. The company had revenue of $4.71 million for the quarter, compared to analysts’ expectations of $5.14 million. HTG Molecular Diagnostics had a negative return on equity of 83.42% and a negative net margin of 74.94%. As a group, analysts predict that HTG Molecular Diagnostics will post -0.71 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Symmetry Peak Management LLC bought a new stake in shares of HTG Molecular Diagnostics during the third quarter valued at about $429,000. Virtu Financial LLC bought a new stake in shares of HTG Molecular Diagnostics during the third quarter valued at about $215,000. Granite Point Capital Management L.P. bought a new stake in shares of HTG Molecular Diagnostics during the third quarter valued at about $1,010,000. FMR LLC raised its stake in shares of HTG Molecular Diagnostics by 2.9% during the third quarter. FMR LLC now owns 3,588,045 shares of the medical research company’s stock valued at $18,120,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of HTG Molecular Diagnostics during the third quarter valued at about $1,089,000. Institutional investors and hedge funds own 46.55% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Featured Story: What are the Benefits of Index Funds?
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.